Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections... see more

Recent & Breaking News (NDAQ:SPRO)

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

GlobeNewswire March 26, 2026

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

GlobeNewswire March 18, 2026

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GlobeNewswire December 19, 2025

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 28, 2025

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

GlobeNewswire November 13, 2025

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

GlobeNewswire November 4, 2025

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

GlobeNewswire October 21, 2025

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

GlobeNewswire October 14, 2025

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

GlobeNewswire August 12, 2025

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

GlobeNewswire August 5, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GlobeNewswire May 28, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

GlobeNewswire May 13, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

GlobeNewswire May 5, 2025

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

GlobeNewswire April 28, 2025

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

GlobeNewswire March 27, 2025

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

GlobeNewswire March 18, 2025

UPDATE - Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 25, 2025

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 25, 2025

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

GlobeNewswire January 10, 2025

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire November 14, 2024

Podcasts